What we have achieved.

Launch of Contractubex^®

Prevention of scars, for fresh or older scars and keloids, promoting the normal wound healing process, anti-inflammatory, anti-redness, reducing swelling, pain and irritation

Launch of Hepa-Merz^®

For the treatment of chronic liver diseases with insufficient hepatic detoxification (e.g. in liver cirrhosis) and its complications (hepatic encephalopathy)

Launch of PK-Merz^®

For the treatment of symptoms of Parkinson‘s disease, such as rigor, tremor and hypo or akinesia, drug-induced extrapyramidal symptoms such as early dyskinesia, akathisia, and parkinsonoid syndrome

Launch of Pantogar^®

Hair and nail therapeutic agent for the treatment of various forms of diffuse hair loss and improvement in hair growth, hair damaged by sunlight and UV radiation and nail growth disorders

Botulinum neurotoxin type A

US approval for the treatment of adults with cervical dystonia and blepharospasm (pre-treated with onabotulinumtoxina)

Cuvposa^®

FDA-approved treatment for the treatment of chronic severe drooling in pediatric patients with neurological conditions, launched as the only liquid formulation on the market, designed with the aim to deliver an individualized dose for patients

Launch of ProlarynTM gel and plus

Proven injectable implants indicated for the treatment of vocal fold insufficiency, providing both short-term and long-term options for patients in a single portfolio

Botulinum neurotoxin type A

• EU approval for the treatment of chronic sialorrhea in adults
• US approval for first-line treatment of adults with blepharospasm
• EU approval for the symptomatic treatment of hemifacial spasm in adults

Start of Merz Therapeutics as an own business

Start of Merz Therapeutics as a dedicated business within the Merz Group committed to serving the unmet needs of patients suffering from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life

Botulinum neurotoxin type A

• Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the treatment of upper limb spasticity in adults
• US approval for the treatment of upper limb spasticity in pediatric patients age 2 to 17, excluding spasticity caused by cerebral palsy
• US approval for the treatment of chronic sialorrhea in patients age 2 and older. The first neurotoxin on the market to treat pediatric patients suffering from sialorrhea

Botulinum neurotoxin type A

• Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the treatment of lower limb spasticity in adults
• EU approval for the symptomatic treatment of chronic sialorrhea due to neurological / neurodevelopmental disorders in children and adolescents age 2 to 17
• Merz and the Israeli start-up Vensica launch strategic partnership for the needleless treatment of overactive bladder delivering Botulinum neurotoxin type A to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter
• UK approval for the treatment of focal spasticity of the lower limb affecting the ankle joint